New hope for hard-to-treat liver metastases from colon cancer

This study tests a new combination treatment for people with advanced colorectal cancer that has spread to the liver and stopped responding to standard therapies. The approach uses a liver-directed chemotherapy infusion (HAIC), an immunotherapy drug (tislelizumab), and targeted drugs chosen based on the tumor's genetic profile from a blood test. The goal is to control the disease and improve survival, not to cure it. About 47 adults with stable or slow-growing tumors are participating.